Beschreibung

mAPPHemo monitors adverse effects from the use of drugs for hemophilia treatment.
Hemophilia is a congenital coagulation disorder caused by the absence or insufficient production of clotting factor VIII (FVIII) in hemophilia A and of clotting factor IX (FIX) in hemophilia B. The symptoms are excessive or unexplained bleeding whose severity generally corresponds to the extent of the FVIII/FIX deficit. Hemophilia can range from severe (spontaneous bleeding, mostly into the muscles and joints, starting in early childhood) to moderate or mild, where bleeding mostly results from injury, surgery, or invasive procedures.
Hemophilia is treated by injecting a concentrate into the bloodstream to replace the deficient clotting factor. These products are either plasma-derived or recombinant, and can be used on demand (to resolve a bleeding episode in course) or prophylactically (at regular intervals to prevent bleeding episodes). In recent years, researchers have explored innovative solutions with a view to developing a new generation of treatment products. We are living in truly historical times for hemophilia treatment, and with an ever-growing number of new drugs coming into widespread use, we need to be extra vigilant that they are safe and effective.
mAPPHemo, developed to the specifications of the Factor VIII, Factor IX and Rare Coagulation Disorders Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH), collects data on the use of these drugs and any side effects experienced by patients. It can be used by individual healthcare facilities or on a region- or nationwide level, allowing clinicians to gather data from everyday clinical practice in the same manner anywhere in the world, so outcomes across populations can be compared. This should ultimately improve patient safety by providing a snapshot of how new hemophilia drugs are being used and what adverse events are reported around the world, shedding light on new side effects and answering questions about products’ long-term safety throughout the population or in specific subgroups.
In addition to the sponsor's scientific pursuits, this project furthers implementation of European Union rules on pharmacovigilance (Directives 2010/84/EU and 2012/26/UE) and the operating procedures for drug safety described in Italy's Ministerial Decree of May 30, 2015. The rationale for the app is to strengthen the drug monitoring system of new hemophilia products that have been or will soon be authorized for sale, and to increase the involvement of patients and healthcare professionals in reporting adverse events to the authorities (Agenzia Italiana del Farmaco [AIFA] and the European Medicines Agency [EMA]).
Finally, an app for doctors and patients through which patients can fill in questionnaires about their health and physicians can check data and patient input will facilitate doctor-patient communication.
Ausblenden Mehr anzeigen...

Screenshots

mAPPHemo Häufige Fragen

  • Ist mAPPHemo kostenlos?

    Ja, mAPPHemo ist komplett kostenlos und enthält keine In-App-Käufe oder Abonnements.

  • Ist mAPPHemo seriös?

    Nicht genügend Bewertungen, um eine zuverlässige Einschätzung vorzunehmen. Die App benötigt mehr Nutzerfeedback.

    Danke für die Stimme

  • Wie viel kostet mAPPHemo?

    mAPPHemo ist kostenlos.

  • Wie hoch ist der Umsatz von mAPPHemo?

    Um geschätzte Einnahmen der mAPPHemo-App und weitere AppStore-Einblicke zu erhalten, können Sie sich bei der AppTail Mobile Analytics Platform anmelden.

Benutzerbewertung
Die App ist in Ecuador noch nicht bewertet.
Bewertungsverlauf

mAPPHemo Bewertungen

Keine Bewertungen in Ecuador
Die App hat noch keine Bewertungen in Ecuador.

Store-Rankings

Ranking-Verlauf
App-Ranking-Verlauf noch nicht verfügbar
Kategorien-Rankings
App ist noch nicht gerankt

mAPPHemo Installationen

Letzte 30 Tage

mAPPHemo Umsatz

Letzte 30 Tage

mAPPHemo Einnahmen und Downloads

Gewinnen Sie wertvolle Einblicke in die Leistung von mAPPHemo mit unserer Analytik.
Melden Sie sich jetzt an, um Zugriff auf Downloads, Einnahmen und mehr zu erhalten.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.